AspirinPlatelet Aggregation InhibitorsAnti-Inflammatory Agents, Non-SteroidalThromboxane B2TiclopidineCyclooxygenase InhibitorsDose-Response Relationship, DrugPlatelet AggregationDrug Therapy, CombinationSalicylatesDrug Administration ScheduleDouble-Blind MethodTime FactorsPlatelet Function TestsRadiation DosageAdministration, OralTreatment OutcomeBlood PlateletsDose-Response Relationship, RadiationSodium SalicylateAnticoagulantsFibrinolytic AgentsHemorrhageWarfarinDrug InteractionsLethal Dose 50Cyclooxygenase 1Asthma, Aspirin-InducedTablets, Enteric-CoatedBleeding TimeIbuprofenProstaglandin-Endoperoxide SynthasesGastrointestinal HemorrhagePlatelet ActivationProspective StudiesThromboxanesThromboxane A2Cyclooxygenase 2 InhibitorsAcetaminophenThrombosisDipyridamoleRadiometryDrug ResistanceRisk FactorsInjections, IntravenousRats, Sprague-DawleyFollow-Up StudiesDrug SynergismMyocardial InfarctionIndomethacinGastric MucosaCyclooxygenase 2Infusions, IntravenousProstaglandinsLipoxinsStomach UlcerRats, WistarHeparinDrug CombinationsRadiotherapy DosageStrokeDinoprostoneSulfinpyrazoneDisease Models, AnimalRecurrenceDose FractionationNaproxenRandom AllocationEpoprostenolReye SyndromeDrug HypersensitivityInjections, Subcutaneous6-Ketoprostaglandin F1 alphaRandomized Controlled Trials as TopicRisk AssessmentPlacebosPyrazoles